Improving the Continuum of Care and Medication Adherence in Patients with Schizophrenia
neuroscienceCME Multimedia SnackPremiere Date: Thursday, May 17, 2012
This activity offers CE credit for:
- Physicians (CME)
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Friday, May 17, 2013
|S. Charles Schulz, MD
Professor and Head
Donald W. Hastings Endowed Chair
Department of Psychiatry
University of Minnesota Medical School
|Meera Narasimhan, MD
Professor and Chairman
Department of Neuropsychiatry and Behavioral Science
University of South Carolina School of Medicine
Medication nonadherence is a multifaceted issue that is linked to both behavioral and system barriers. Behavioral barriers include lack of social support, cognition, and personal beliefs (e.g., regarding health). System barriers include treatment complexity (multiple medications/dosing schedule), system complexity (multiple providers), and cost.(1)
In individuals with schizophrenia, poor adherence to treatment can result in worsening of symptoms, relapse, worsening of overall condition, increased utilization of health care facilities, rehospitalization, reduced quality of life, social alienation, increased substance abuse, unemployment, violence, high rates of victimization, incarceration, and death.(2) Despite this, clinicians generally fail to ask about adherence to prescribed antipsychotic medication.(2)
This neuroscienceCME Snack focuses on nonadherence to taking antipsychotic medication among patients with schizophrenia. Participants will learn to identify some of the causes for, and illustrate the consequences of, nonadherence; increase rates at which they ask patients about nonadherence; and implement strategies in clinical practice that minimize nonadherence.
- Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm. 2008;14(6 Suppl S-d):S2-S10.
- Narasimhan M, Harding RK, Hardeman SM. Simplifying adherence in schizophrenia. Psychiatr Serv. 2010;61(4):405-408.
Increase recognition of the causes of, and consequences for, nonadherence to taking antipsychotic medications, increase rates at which clinicians ask patients about adherence, and encourage clinicians to implement strategies in clinical practice to reduce medication nonadherence among patients with schizophrenia.
At the end of this CE activity, participants should be able to:
- Identify some of the causes for, and illustrate the consequences of, nonadherence to taking antipsychotic medications among patients with schizophrenia.
- Increase rates at which they ask patients with schizophrenia about medication adherence
- Define and implement strategies in clinical practice that minimize nonadherence to taking antipsychotic medication among patients with schizophrenia.
Physicians and nonphysician health care professionals with an interest in schizophrenia.
USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from AstraZeneca Pharmaceuticals in support of this CE activity.
This activity is supported by an independent educational grant from Cephalon, Inc.
This program is supported by an educational grant from Janssen, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Supported by an educational grant from Pfizer Inc.
USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Sunovion Pharmaceuticals Inc. in support of this CE activity.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Narasimhan has disclosed that she receives grants from Bristol-Myers Squibb Company, Forest Laboratories, Inc., Janssen, L.P., National Institute of Health, and Otsuka America Pharmaceutical, Inc. She has served on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Eli Lilly and Company.
Dr. Schulz has disclosed that he serves on the advisory boards Biovail Pharmaceuticals, Inc., and Eli Lilly and Company. He receives grants and research support from AstraZeneca Pharmaceuticals LP and Eli Lilly and Company.
Tony Graham, MD (content/peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, AstraZeneca Pharmaceuticals, Cephalon Inc., Ortho-McNeil Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC, Lilly, Pfizer Inc., and Sunovion Pharmaceuticals do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).